IGF-1 neutralizing antibody

An **IGF-1 neutralizing antibody** is a monoclonal antibody designed to bind to and neutralize insulin-like growth factor 1 (IGF-1), a polypeptide hormone that plays a key role in cell growth, proliferation, and survival. By binding to circulating or local IGF-1, these antibodies prevent it from interacting with its receptor, the insulin-like growth factor 1 receptor (IGF-1R), thereby inhibiting downstream signaling pathways such as PI3K/Akt and MAPK. In oncology, IGF-1 neutralizing antibodies are investigated for their potential to inhibit tumor cell invasion, metastasis, and resistance to therapies (such as BRAF/MEK inhibitors or EGFR tyrosine kinase inhibitors) that can be mediated by stromal or tumor-derived IGF-1. They are also utilized as research reagents in preclinical studies to elucidate the role of the IGF-1 signaling axis in various physiological and pathological processes, including obesity-induced cancer progression and neuropathic pain.

Other names

anti-IGF-1 antibodyanti-IGF1 antibodyanti-IGF 1 antibodyanti-IGF-1 monoclonal antibodyanti-IGF1 monoclonal antibodyanti-IGF 1 monoclonal antibodyanti-insulin-like growth factor 1 antibodyIGF-1 antibodyIGF1 antibodyIGF 1 antibodyIGF-1 blockerIGF1 blockerIGF 1 blockerIGF-1 inhibitorIGF1 inhibitorIGF 1 inhibitor